Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix

Summary

The aminopeptidase inhibitor bestatin has been shown to have anti-angiogenic effects in a number of model systems. These effects are thought to result from inhibition of CD13 activity. Because tumor angiogenesis can evolve in a fibrin-rich stroma matrix we have studied for the first time the effects of bestatin on microvascular endothelial capillary-like tube formation in a fibrin matrix. Bestatin enhanced the formation of capillary-like tubes dose-dependently. Its effects were apparent at 8 µM; the increase was 3.7-fold at 125 µM; while high concentrations (>250 µM), that were shown to have anti-angiogenic effects in other systems, caused extensive matrix degradation. Specific CD13-blocking antibodies WM15 and MY-7, and the aminopeptidase inhibitors amastatin and actinonin also enhanced capillary-like tube formation (maximally 1.5-fold), but these effects did not reach statistical significance. The effect of bestatin was not due to a change in uPAR availability because the relative involvement of the u-PA/u-PAR activity was not altered by bestatin. In view of the present findings we hypothesize that aminopeptidases other than CD13 predominantly contribute to the observed pro-angiogenic effect of bestatin in a fibrin matrix. The identification of this novel effect of bestatin is important in the light of the proposed use of bestatin as anti-angiogenic and/or anti-tumor agent.

Keywords

Bestatin - CD13 - angiogenesis - fibrin - u-PAR

• References

• 1 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
• 2 Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
• 3 van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 1997; 79: 391-411.
• 4 Koolwijk P, van Erck MG, de Vree WJ. et al Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.
• 5 Pepper MS, Belin D, Montesano R. et al Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743-55.
• 6 Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vas Biol 2001; 21: 1104-17.
• 7 Murphy G, Stanton H, Cowell S. et al Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44.
• 8 Andolfo A, English WR, Resnati M. et al Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 2002; 88: 298-306.
• 9 Koolwijk P, Sidenius N, Peters E. et al Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001; 97: 3123-31.
• 10 Collen A, Hanemaaijer R, Lupu F. et al Membrane-type matrix metalloproteinase mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101: 1810-7.
• 11 Hiraoka N, Allen E, Apel IJ. et al Matrix met-alloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
• 12 Lafleur MA, Handsley MM, Knauper V. et al Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115: 3427-38.
• 13 Umezawa H, Aoyagi T, Suda H. et al Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 1976; 29: 97-9.
• 14 Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Current Drug Metabolism 2002; 2: 67-85.
• 15 Ota K. Review of ubenimex (Bestatin): clinical research. Biomed Pharmacother 1991; 45: 55-60.
• 16 Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy 1992; 4: 205-14.
• 17 Bhagwat SV, Lahdenranta J, Giordano R. et al CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001; 97: 652-9.
• 18 Pasqualini R, Koivunen E, Kain R. et al Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angio-genesis. Cancer Res 2000; 60: 722-7.
• 19 Bhagwat SV, Petrovic N, Okamoto Y. et al The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 2003; 101: 1818-26.
• 20 Hashida H, Takabayashi A, Kanai M. et al Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002; 122: 376-86.
• 21 van Hensbergen Y, Broxterman HJ, Hanemaaijer R. et al Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 2002; 8: 3747-54.
• 22 van Hinsbergh VWM, Draijer R. Culture and characterization of human endothelial cells. In: Oxford University Press. Shaw AJ 1996; 87-110.
• 23 Favaloro EJ. CD-13 (‘gp150’; aminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity. Immunol Cell Biol 1991; 69: 253-60.
• 24 van Hensbergen Y, Broxterman HJ, Elderkamp YW. et al A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol 2002; 63: 897-908.
• 25 Xu Y, Lai LT, Gabrilove JL. et al Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 1998; 4: 171-6.
• 26 Gao B, Saba TM, Tsan MF. Role of alpha(v)beta(3)-integrin in TNF-alpha-induced endothelial cell migration. Am J Physiol Cell Physiol 2002; 283: 1196-1205.
• 27 Rüegg C, Dormond O, Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?. Endothelium 2002; 9: 151-60.
• 28 Kroon ME, Koolwijk P, van Goor H. et al Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 1999; 154: 1731-42.
• 29 van Hinsbergh VW, van den Berg EA, Fiers W. et al Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-8.
• 30 Emeis JJ, Verheijen JH, Ronday HK. et al Progress in clinical fibrinolysis. Fibrinolysis Poteolysis 1997; 11: 67-84.
• 31 Takeuchi T, Harris JL, Huang W. et al Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
• 32 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
• 33 Collen A, Smorenburg SM, Peters E. et al Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60: 6196-6200.
• 34 Collen A, Maas A, Kooistra T. et al Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-80.
• 35 Collen A, Koolwijk P, Kroon ME. et al Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angio-genesis 1998; 2: 153-65.
• 36 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.